AstraZeneca announces US to purchase additional 500,000 doses of Evusheld
Content of the article
AstraZeneca> said on Wednesday that the U.S. government had agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to treat COVID-19.
The company said delivery of the doses is expected in the first quarter of 2022 and more details of the deal will be announced in the coming weeks.
The additional doses will come on top of a previous purchase of 700,000 doses of the antibody therapy, which in December was shown to retain neutralizing activity against the highly transmissible variant of the Omicron coronavirus in a laboratory study.
Last month, the United States Food and Drug Administration cleared Evusheld to prevent COVID-19 infections in people with weakened immune systems or who have a history of serious side effects from coronavirus vaccines.
It is the only antibody therapy authorized in the United States to prevent symptoms of COVID-19 before exposure to the virus, the company said.
(Report by Aby Jose Koilparambil and Manojna Maddipatla in Bangalore)